

# Corneal Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C4B2D127429BEN.html>

Date: May 2024

Pages: 132

Price: US\$ 6,499.00 (Single User License)

ID: C4B2D127429BEN

## Abstracts

The 7 major corneal dystrophy markets are expected to exhibit a CAGR of 6.1% during 2024-2034.

The corneal dystrophy market has been comprehensively analyzed in IMARC's new report titled "Corneal Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Corneal dystrophy refers to a group of rare, inherited eye disorders characterized by the abnormal accumulation of material in the cornea, the clear outermost layer of the eye. This buildup disrupts the normal functioning of the corneal cells, leading to impaired vision and discomfort. The indications of the ailment can vary depending on the specific type, but often include blurred or cloudy vision, sensitivity to light, and the sensation of a foreign material in the eye. As these dystrophies are progressive in nature, symptoms tend to worsen over time, impacting visual acuity and overall quality of life. Diagnosing the illness involves a comprehensive eye examination performed by an ophthalmologist. Visual acuity tests, corneal thickness measurements, and specialized imaging techniques like corneal topography may be performed to evaluate the extent of corneal involvement. Additionally, a detailed medical and family history can aid in identifying any genetic predisposition to these conditions.

The increasing cases of mutations in specific genes that are responsible for maintaining the regular structure and function of the cornea are primarily driving the corneal dystrophy market. In addition to this, the inflating utilization of cutting-edge treatments, including corneal cross-linking, phototherapeutic keratectomy, endothelial keratoplasty, etc., to manage the disorder and mitigate its progression is also creating a positive outlook for the market. Moreover, the widespread adoption of specialized therapies,

such as the use of hypertonic saline solutions and therapeutic contact lenses, which aid in alleviating symptoms and enhancing corneal health, is further bolstering the market growth. Apart from this, the rising demand for innovative techniques like Descemet's membrane endothelial keratoplasty (DMEK) and Descemet's stripping automated endothelial keratoplasty (DSAEK) to help in addressing specific variations of corneal dystrophy is acting as another significant growth-inducing factor. These methods work by targeting precise layers of the cornea to offer more tailored and effective treatment approaches. Additionally, the emerging popularity of genetic interventions, encompassing gene editing and gene replacement strategies, to correct or replace malfunctioning genes associated with the condition is also augmenting the market growth. Furthermore, the ongoing advancements in diagnostic technologies, including confocal microscopy and high-resolution ultrasound, that can enable early detection and accurate characterization of the dystrophies are expected to drive the corneal dystrophy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the corneal dystrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for corneal dystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the corneal dystrophy market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the corneal dystrophy market  
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the corneal dystrophy market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current corneal dystrophy marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report

## Market Insights

How has the corneal dystrophy market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the corneal dystrophy market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the corneal dystrophy market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of corneal dystrophy across the seven major markets?

What is the number of prevalent cases (2018-2034) of corneal dystrophy by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of corneal dystrophy by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of corneal dystrophy by type across the seven major markets?

How many patients are diagnosed (2018-2034) with corneal dystrophy across the seven major markets?

What is the size of the corneal dystrophy patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of corneal dystrophy?

What will be the growth rate of patients across the seven major markets?

## Corneal Dystrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for corneal dystrophy drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the corneal dystrophy market?

What are the key regulatory events related to the corneal dystrophy market?

What is the structure of clinical trial landscape by status related to the corneal dystrophy market?

What is the structure of clinical trial landscape by phase related to the corneal dystrophy market?

What is the structure of clinical trial landscape by route of administration related to the corneal dystrophy market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 CORNEAL DYSTROPHY - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 CORNEAL DYSTROPHY - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 CORNEAL DYSTROPHY - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Epidemiology by Type (2018-2034)
  - 7.2.6 Diagnosed Cases (2018-2034)
  - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Epidemiology by Type (2018-2034)
  - 7.3.6 Diagnosed Cases (2018-2034)
  - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Epidemiology by Type (2018-2034)
  - 7.4.6 Diagnosed Cases (2018-2034)
  - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Epidemiology by Type (2018-2034)
  - 7.5.6 Diagnosed Cases (2018-2034)
  - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Epidemiology by Type (2018-2034)
  - 7.6.6 Diagnosed Cases (2018-2034)

- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)
  - 7.7.4 Epidemiology by Gender (2018-2034)
  - 7.7.5 Epidemiology by Type (2018-2034)
  - 7.7.6 Diagnosed Cases (2018-2034)
  - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Epidemiology by Type (2018-2034)
  - 7.8.6 Diagnosed Cases (2018-2034)
  - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Epidemiology by Type (2018-2034)
  - 7.9.6 Diagnosed Cases (2018-2034)
  - 7.9.7 Patient Pool/Treated Cases (2018-2034)

## **8 CORNEAL DYSTROPHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 CORNEAL DYSTROPHY - UNMET NEEDS**

## **10 CORNEAL DYSTROPHY - KEY ENDPOINTS OF TREATMENT**

## **11 CORNEAL DYSTROPHY - MARKETED PRODUCTS**

- 11.1 List of Corneal Dystrophy Marketed Drugs Across the Top 7 Markets



- 11.1.1 Drug Name – Company Name
  - 11.1.1.1 Drug Overview
  - 11.1.1.2 Mechanism of Action
  - 11.1.1.3 Regulatory Status
  - 11.1.1.4 Clinical Trial Results
  - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

## **12 CORNEAL DYSTROPHY - PIPELINE DRUGS**

- 12.1 List of Corneal Dystrophy Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 Ripasudil - D Western Therapeutics Institute/Kowa Pharmaceutical
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results
    - 12.1.1.4 Safety and Efficacy
    - 12.1.1.5 Regulatory Status
  - 12.1.2 STN1010904 - ActualEyes/Santen Pharmaceutical
    - 12.1.2.1 Drug Overview
    - 12.1.2.2 Mechanism of Action
    - 12.1.2.3 Clinical Trial Results
    - 12.1.2.4 Safety and Efficacy
    - 12.1.2.5 Regulatory Status
  - 12.1.3 TTHX 1114 - Trefoil Therapeutics
    - 12.1.3.1 Drug Overview
    - 12.1.3.2 Mechanism of Action
    - 12.1.3.3 Clinical Trial Results
    - 12.1.3.4 Safety and Efficacy
    - 12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. CORNEAL DYSTROPHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. CORNEAL DYSTROPHY – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

## **15 CORNEAL DYSTROPHY - MARKET SCENARIO**

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Corneal Dystrophy - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Corneal Dystrophy - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Corneal Dystrophy - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Corneal Dystrophy - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Corneal Dystrophy - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Corneal Dystrophy - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Corneal Dystrophy - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Corneal Dystrophy - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Corneal Dystrophy - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Corneal Dystrophy - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Corneal Dystrophy - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Corneal Dystrophy - Market Size

- 15.6.1.1 Market Size (2018-2023)
- 15.6.1.2 Market Forecast (2024-2034)
- 15.6.2 Corneal Dystrophy - Market Size by Therapies
  - 15.6.2.1 Market Size by Therapies (2018-2023)
  - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Corneal Dystrophy - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Corneal Dystrophy - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Corneal Dystrophy - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Corneal Dystrophy - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Corneal Dystrophy - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Corneal Dystrophy - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Corneal Dystrophy - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Corneal Dystrophy - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Corneal Dystrophy - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Corneal Dystrophy - Access and Reimbursement Overview

## **16 CORNEAL DYSTROPHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 CORNEAL DYSTROPHY MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities

17.4 Threats

**18 CORNEAL DYSTROPHY MARKET – STRATEGIC RECOMMENDATIONS**

**19 APPENDIX**

## I would like to order

Product name: Corneal Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C4B2D127429BEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C4B2D127429BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

